Drugs Approved By the FDA for Blood Cancers in 2014 Show Lack of Progress by Pharmaceutical Industry

In 2014, Dr. Richard Pazdur and the Office of Oncology Drug Products at the U.S. Food and Drug Administration approved six drugs for hematologic cancers.

Unfortunately, the six drugs approved are only indicated to treat the following three subtypes:

  • Peripheral T-cell lymphoma (PTCL), one new drug
  • Acute lymphoblastic lymphoma (ALL), two new drugs
  • Chronic lymphocytic leukemia (CLL), three new drugs

To make matters worse, these drugs will serve extremely small patient populations. Together, the three diseases account for about 30,000 new diagnoses each year (ALL: 5,000, PTCL: 10,000, CLL: 15,000). The approval of another three drugs to treat chronic lymphocytic leukemia illustrates the utter absence of innovation or imagination at major pharmaceutical companies, since every CLL drug (there are now seven) simply piggy-backs on the success of Novartis' Gleevec.

Peripheral T-Cell Lymphoma

DRUG: Belinostat (Beleodaq)
APPROVAL TYPE: Accelerated
INDICATION: Patients with relapsed or refractory peripheral T-cell lymphoma.

Acute Lymphoblastic Leukemia (ALL)

DRUG: Mercaptopurine (Purixan) in oral suspension in combination with other drugs.
INDICATION: Treatment of patients with acute lymphoblastic leukemia (ALL).

DRUG: Blinatumomab (Blincyto)
APPROVAL TYPE: Accelerated
INDICATION: Treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell ALL.

Chronic Lymphocytic Leukemia (CLL)

DRUG: Ibrutinib (Imbruvica)
APPROVAL TYPE: Accelerated
INDICATION: Treatment of patients with chronic lymphocytic leukemia (CLL) with a history of at least one prior therapy.

DRUG: Ofatumumab (Arzerra) in combination with chlorambucil
INDICATION: Treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is not appropriate.

DRUG: Idelalisib (Zydelig) in combination with rituximab
INDICATION: Patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy because of existing comorbidities.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...